Drug Safety Meta-Analyses: US FDA Emphasizes Trial Quality Over Quantity
Executive Summary
Three years overdue, agency draft guidance seeks to inject a threshold level of rigor into meta-analyses of randomized, controlled trials to evaluate drug safety and proposes a three-tiered hierarchy of evidence against which FDA will evaluate such studies for regulatory decision-making purposes.